Review



recombinant gzma  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress recombinant gzma
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Recombinant Gzma, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/GZMA%2FGranzyme+A%2C+Mouse/pmc13198314-66-0-3
    Average 94 stars, based on 1 article reviews
    recombinant gzma - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma"

    Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2026.102754

    GZMA-F2R interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Figure Legend Snippet: GZMA-F2R interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .

    Techniques Used: Activation Assay, Expressing, Multicolor Immunofluorescence Staining

    Related Articles

    Recombinant:

    Article Title: Granzyme K + CD8 + T cells interact with fibroblasts to promote neutrophilic inflammation in nasal polyps
    Article Snippet: .. Cells were stimulated with 100 ng/ml of human recombinant GZMK (ProSpec, Ness-Ziona, Israel), 100 ng/ml of human recombinant GZMA (MedChemExpress, Monmouth Junction, NJ, USA), or 100 ng/ml of human recombinant GZMB (Abclonal, Wuhan, China) for 6 h, with the culture medium used as the control . ..

    Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma.
    Article Snippet: Flow cytometric data were acquired on a BD FACSVerse and analyzed using FlowJo software. .. Flow cytometry of human HCC TILs To evaluate the impact of the GZMA-F2R signaling on CD8 + TIL activation, the in vitro-expanded TILs were seeded in 24-well plates, pre-treated with the F2R antagonist SCH79797 (MCE, 5 μM), and subsequently stimulated with recombinant GZMA (MCE, 0.05 ng/ mL). ..

    Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma
    Article Snippet: SCH79797 (F2R antagonist, F2RA) , MCE , Cat#HY-14994. .. Recombinant GZMA , MCE , Cat#HY- P76377. .. OKT3 , T&L biotechnology , Cat#GMP-TL101-0500.

    Control:

    Article Title: Granzyme K + CD8 + T cells interact with fibroblasts to promote neutrophilic inflammation in nasal polyps
    Article Snippet: .. Cells were stimulated with 100 ng/ml of human recombinant GZMK (ProSpec, Ness-Ziona, Israel), 100 ng/ml of human recombinant GZMA (MedChemExpress, Monmouth Junction, NJ, USA), or 100 ng/ml of human recombinant GZMB (Abclonal, Wuhan, China) for 6 h, with the culture medium used as the control . ..

    Flow Cytometry:

    Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma.
    Article Snippet: Flow cytometric data were acquired on a BD FACSVerse and analyzed using FlowJo software. .. Flow cytometry of human HCC TILs To evaluate the impact of the GZMA-F2R signaling on CD8 + TIL activation, the in vitro-expanded TILs were seeded in 24-well plates, pre-treated with the F2R antagonist SCH79797 (MCE, 5 μM), and subsequently stimulated with recombinant GZMA (MCE, 0.05 ng/ mL). ..

    Activation Assay:

    Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma.
    Article Snippet: Flow cytometric data were acquired on a BD FACSVerse and analyzed using FlowJo software. .. Flow cytometry of human HCC TILs To evaluate the impact of the GZMA-F2R signaling on CD8 + TIL activation, the in vitro-expanded TILs were seeded in 24-well plates, pre-treated with the F2R antagonist SCH79797 (MCE, 5 μM), and subsequently stimulated with recombinant GZMA (MCE, 0.05 ng/ mL). ..



    Similar Products

    94
    MedChemExpress recombinant gzma
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Recombinant Gzma, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/GZMA%2FGranzyme+A%2C+Mouse/pmc13198314-66-0-3
    Average 94 stars, based on 1 article reviews
    recombinant gzma - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress 14994 recombinant gzma mce cat
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    14994 Recombinant Gzma Mce Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/GZMA%2FGranzyme+A%2C+Mouse/pm42013842-277-127-130
    Average 94 stars, based on 1 article reviews
    14994 recombinant gzma mce cat - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress recombinant mouse il 13
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Recombinant Mouse Il 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/GZMA%2FGranzyme+A%2C+Mouse/10__34133_slash_research__1190-170-12-19
    Average 94 stars, based on 1 article reviews
    recombinant mouse il 13 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    91
    Cusabio recombinant mouse gzma
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Recombinant Mouse Gzma, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/GZMA/pm41606670-126-12-15
    Average 91 stars, based on 1 article reviews
    recombinant mouse gzma - by Bioz Stars, 2026-10
    91/100 stars
      Buy from Supplier

    94
    MedChemExpress mouse recombinant granzyme a
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Mouse Recombinant Granzyme A, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/GZMA%2FGranzyme+A%2C+Human/pmc12663269-434-10-18
    Average 94 stars, based on 1 article reviews
    mouse recombinant granzyme a - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    90
    AtaGenix Inc recombinant human gzma ya9870
    <t>GZMA-F2R</t> interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .
    Recombinant Human Gzma Ya9870, supplied by AtaGenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+gzma/recombinant+human+gzma++ya9870+/pm39367435-37-0-7
    Average 90 stars, based on 1 article reviews
    recombinant human gzma ya9870 - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    GZMA-F2R interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .

    Journal: Cell Reports Medicine

    Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma

    doi: 10.1016/j.xcrm.2026.102754

    Figure Lengend Snippet: GZMA-F2R interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .

    Article Snippet: Recombinant GZMA , MCE , Cat#HY- P76377.

    Techniques: Activation Assay, Expressing, Multicolor Immunofluorescence Staining